



ZENITH DRUGS LIMITED
(Formerly - Zenith Drugs Private Limited)
CONTACT US:

-  www.zenithdrugs.com
-  info@zenithdrugs.com
-  +91 93291 45074 CIN: L24231MP2000PLC014465
-  **Plant Add. - 72/5 & 72/1, 72/3, 74/1/1, 75/1/1 Muradpura (Orangpura),
Dhar Road, Near Kalarla, INDORE, PIN-453001 (MP) INDIA**



Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: October 13, 2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Sub: Outcome of Meeting of Board of Directors held on October 13, 2026.

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Dear Sir/Ma'am,

Pursuant to Regulations 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held on October 13, 2026, inter alia, considered and approved the sale of land and Building situated at Plot No. UD-7, Industrial Park, Mohana, District Indore, Madhya Pradesh, for a consideration of ₹13,75,00,000/- (Rupees Thirteen Crore Seventy Five Lacs Only).

The details required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular are enclosed as Annexure A.

The Board meeting commenced at 02:00 P.M. and concluded at 02:33 P.M.

Thanking you
Yours faithfully

For Zenith Drugs Limited

SAKSHI BHAWSAR
Digitally signed by SAKSHI BHAWSAR
Date: 2026.10.13 14:40:06 +05'30'

SAKSHI BHAWSAR
Company Secretary and Compliance Officer

ANNEXURE A

Information as per SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Regulation 30 of the Listing Regulations:

Sr. No	Particulars	Details
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	It is an immovable property (land and building) admeasuring 5 hectare. The property contributes to 0% of turnover/revenue. Its value represents approximately 18.57% of the net worth of the Company as per the audited financial statements for FY 2025-26.
2	Date on which the agreement for sale has been entered into	The Sale Deed is proposed to be executed on or before October 20, 2026.
3	The expected date of completion of sale/disposal	on or before November 20, 2026.
4	Consideration received from such sale/disposal	The agreed sale consideration is ₹13,75,00,000/- (Rupees Thirteen Crore Seventy Five Lacs Only) which is expected to be received on or before November 20, 2026.
5	Brief details of buyer and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Brief Details of buyer: M/s ACE Engineering & Chemicals Private Limited (CIN: U25209MP2006PTC018836). Buyer does not belong to promoter/promoter group/group company.
6	Whether the transaction would fall within related party transaction? If yes, whether the same is done at arm's length"	No, the transaction does not fall within the ambit of a related party transaction under Section 188 of the Companies Act, 2013 and Regulation 23 of the Listing Regulations. The transaction is being undertaken on an arm's length basis.
7	whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same include compliance with regulation 37A of LODR Regulations.	The transaction pertains to the sale of land and building and is outside any Scheme of Arrangement. The property does not constitute an "undertaking" within the meaning of the Explanation to Section 180(1) of the Companies Act, 2013; accordingly, approval of the Members under Section 180(1)(a) of the Companies Act, 2013 and Regulation 37A of the Listing Regulations is not required.
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable, as the transaction does not involve a slump sale.